Gjin Ndrepepa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6570674/publications.pdf

Version: 2024-02-01

159 papers	5,683 citations	109137 35 h-index	88477 70 g-index
163 all docs	163 docs citations	163 times ranked	7200 citing authors

#	Article	IF	Citations
1	Efficacy and Safety of Ticagrelor Versus Prasugrel in Women and Men with Acute Coronary Syndrome: A Pre-specified, Sex-Specific Analysis of the ISAR-REACT 5 Trial. Journal of Atherosclerosis and Thrombosis, 2022, 29, 747-761.	0.9	4
2	Prediction of risk for bleeding, myocardial infarction and mortality after percutaneous coronary intervention in patients with acute coronary syndromes. Coronary Artery Disease, 2022, Publish Ahead of Print, .	0.3	2
3	Preadmission antiplatelet therapy and treatment effect of ticagrelor versus prasugrel in patients with acute coronary syndromes - a subgroup analysis of the ISAR-REACT 5 trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	1
4	Periprocedural myocardial injury according to optical characteristics of neointima and treatment modality of in-stent restenosis. Clinical Research in Cardiology, 2022, 111, 827-837.	1.5	2
5	One-Year Ischemic and Bleeding Events According to Renal Function in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Third-Generation Antiplatelet Drugs. American Journal of Cardiology, 2022, 176, 15-23.	0.7	3
6	Alkaline phosphatase and prognosis in patients with diabetes mellitus and ischemic heart disease. Clinica Chimica Acta, 2022, 533, 1-7.	0.5	2
7	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. European Heart Journal, 2021, 42, 323-334.	1.0	68
8	Creatine kinase and bleeding in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2021, 51, e13514.	1.7	0
9	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal, 2021, 42, 2630-2642.	1.0	69
10	Prognostic value of haemoglobin drop in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2021, 51, e13670.	1.7	3
11	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to EstimatedÂGlomerular Filtration Rate. JACC: Cardiovascular Interventions, 2021, 14, 1857-1866.	1.1	9
12	Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance, MDRD-4, CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes. Clinica Chimica Acta, 2021, 523, 106-113.	0.5	9
13	Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes. Clinical Research in Cardiology, 2021, , 1.	1.5	3
14	Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes. Revista Espanola De Cardiologia (English Ed), 2021, , .	0.4	0
15	Procedural and clinical performance of dualâ€versus singleâ€catheter strategy for transradial coronary angiography: A metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2020, 96, 276-282.	0.7	2
16	Relation of Hypocholesterolemia With Diabetes Mellitus in Patients With Coronary Artery Disease. American Journal of Cardiology, 2020, 125, 1026-1032.	0.7	1
17	Hypocholesterolaemia and mortality in patients with coronary artery disease. European Journal of Clinical Investigation, 2020, 50, e13194.	1.7	7
18	Aspartate aminotransferase and mortality in patients with ischemic heart disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2335-2342.	1.1	8

#	Article	IF	Citations
19	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. Annals of Internal Medicine, 2020, 173, 436-444.	2.0	44
20	Long-Term Outcomes of Patients with Unprotected Left Main Coronary Artery Disease Treated with Percutaneous Angioplasty versus Bypass Grafting: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2020, 9, 2231.	1.0	5
21	Ticagrelor or Prasugrel in Patients With ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2020, 142, 2329-2337.	1.6	26
22	Epicardial adipose tissue: An anatomic component of obesity & metabolic syndrome in close proximity to myocardium & coronary arteries. Indian Journal of Medical Research, 2020, 151, 509.	0.4	0
23	Sex differences in the outcome after percutaneous coronary intervention â€“ A propensity matching analysis. Cardiovascular Revascularization Medicine, 2019, 20, 101-107.	0.3	17
24	Inverse association of alanine aminotransferase within normal range with prognosis in patients with coronary artery disease. Clinica Chimica Acta, 2019, 496, 55-61.	0.5	15
25	Research update for articles published in EJCI in 2017. European Journal of Clinical Investigation, 2019, 49, e13163.	1.7	0
26	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 2019, 381, 1524-1534.	13.9	543
27	U-shaped association of central pulse pressure with long-term prognosis after ST-segment elevation myocardial infarction. Heart and Vessels, 2019, 34, 1104-1112.	0.5	3
28	Relationship of left ventricular endâ€diastolic pressure with extent of myocardial ischemia, myocardial salvage and longâ€term outcome in patients with STâ€segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2019, 93, 901-909.	0.7	8
29	Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction. Journal of Translational Medicine, 2019, 17, 180.	1.8	12
30	Myeloperoxidase â€“ A bridge linking inflammation and oxidative stress with cardiovascular disease. Clinica Chimica Acta, 2019, 493, 36-51.	0.5	252
31	Association of shock index with short-term and long-term prognosis after ST-segment elevation myocardial infarction. Coronary Artery Disease, 2019, 30, 575-583.	0.3	5
32	Relation of Ratio of Left Ventricular Ejection Fraction to Left Ventricular End-Diastolic Pressure to Long-Term Prognosis After ST-Segment Elevation Acute Myocardial Infarction. American Journal of Cardiology, 2019, 123, 199-205.	0.7	9
33	High-sensitivity cardiac troponin T in patients with ST-segment elevation myocardial infarction. Journal of Cardiology, 2019, 73, 333-334.	0.8	0
34	Rebuttal: Comparative prognostic value of postprocedural creatine kinase myocardial band and highâ€sensitivity troponin T in patients with nonâ€STâ€segment elevation myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 92, 635-636.	0.7	4
35	Markers of Reperfusion and Long-Term (8-Year) Prognosis after Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2018, 122, 39-46.	0.7	4
36	Elevated serum uric acid. Coronary Artery Disease, 2018, 29, 183-185.	0.3	2

#	Article	IF	Citations
37	High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. Journal of Cardiology, 2018, 72, 220-226.	0.8	15
38	Comparative prognostic value of postprocedural creatine kinase myocardial band and highâ€sensitivity troponin T in patients with nonâ€ST‐segment elevation myocardial infarction undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 91, 215-223.	0.7	16
39	A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 64-70.	1.1	8
40	Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clinica Chimica Acta, 2018, 476, 130-138.	0.5	109
41	Postprocedural high-sensitivity troponin T and prognosis in patients with non-ST-segment elevation myocardial infarction treated with early percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2018, 19, 480-486.	0.3	5
42	Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. Circulation: Cardiovascular Interventions, 2018, 11, e006752.	1.4	32
43	Uric acid and cardiovascular disease. Clinica Chimica Acta, 2018, 484, 150-163.	0.5	300
44	Creatine kinase myocardial band - a biomarker to assess prognostically relevant periprocedural myocardial infarction. International Journal of Cardiology, 2018, 270, 118-119.	0.8	9
45	Bioresorbable vascular scaffold failure â€“ Post factum research to look for the reasons. International Journal of Cardiology, 2018, 268, 96-97.	0.8	2
46	Deferred vs Immediate Stenting in Primary Percutaneous Coronary Intervention: A Collaborative Meta-analysis of Randomized Trials With Cardiac Magnetic Resonance Imaging Data. Canadian Journal of Cardiology, 2018, 34, 1573-1580.	0.8	10
47	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention, 2018, 13, 1565-1573.	1.4	35
48	No-reflow after percutaneous coronary intervention: a correlate of poor outcome in both persistent and transient forms. EuroIntervention, 2018, 14, 139-141.	1.4	1
49	Reply. Journal of the American College of Cardiology, 2017, 69, 1994-1995.	1.2	0
50	Reperfusion injury in ST-segment elevation myocardial infarction. Coronary Artery Disease, 2017, 28, 253-262.	0.3	17
51	Prognostic value of alkaline phosphatase in patients with acute coronary syndromes. Clinical Biochemistry, 2017, 50, 828-834.	0.8	11
52	Alkaline phosphatase and prognosis in patients with coronary artery disease. European Journal of Clinical Investigation, 2017, 47, 378-387.	1.7	36
53	Gamma-glutamyl transferase and atrial fibrillation in patients with coronary artery disease. Clinica Chimica Acta, 2017, 465, 17-21.	0.5	11
54	Research update for articles published in EJCI in 2015. European Journal of Clinical Investigation, 2017, 47, 775-788.	1.7	0

#	Article	IF	Citations
55	Gender disparities in acute coronary syndromes - The way things stand in the sub-Himalayan state of Himachal Pradesh in Northern India. International Journal of Cardiology, 2017, 248, 82-83.	0.8	0
56	Response to the letter to the editor: Mortality risk of elevated alkaline phosphatase in patients with coronary artery disease and percutaneous coronary intervention. Clinical Biochemistry, 2017, 50, 1328-1329.	0.8	0
57	A pan-coronary artery angiographic study of the association between diabetes mellitus and progression or regression of coronary atherosclerosis. Heart and Vessels, 2017, 32, 376-384.	0.5	12
58	Tolvaptan in the very elderly with acute decompensated heart failure- a therapeutic option worthy of consideration. Anatolian Journal of Cardiology, 2017, 18, 213-214.	0.5	1
59	Atherosclerosis & ischaemic heart disease: Here to stay or gone tomorrow. Indian Journal of Medical Research, 2017, 146, 293-297.	0.4	0
60	Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. American Heart Journal, 2016, 177, 9-16.	1.2	15
61	Prognostic value of gamma-glutamyl transferase in patients with diabetes mellitus and coronary artery disease. Clinical Biochemistry, 2016, 49, 1127-1132.	0.8	8
62	Prognostic Value of High-sensitivity Troponin T After Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease. Revista Espanola De Cardiologia (English Ed), 2016, 69, 746-753.	0.4	4
63	High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2016, 68, 2259-2268.	1.2	88
64	Coronary artery thrombus in patients with ST-segment elevation myocardial infarction. Coronary Artery Disease, 2016, 27, 532-534.	0.3	1
65	Increased bleeding risk during percutaneous coronary interventions by arterial hypertension. Catheterization and Cardiovascular Interventions, 2016, 88, 184-190.	0.7	6
66	Comparison of drug-eluting balloon versus drug-eluting stent treatment of drug-eluting stent in-stent restenosis: A meta-analysis of available evidence. International Journal of Cardiology, 2016, 218, 126-135.	0.8	20
67	Gamma-glutamyl transferase and prognosis in patients with coronary artery disease. Clinica Chimica Acta, 2016, 452, 155-160.	0.5	19
68	Relation of Gamma-Glutamyl Transferase to Cardiovascular Events in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2016, 117, 1427-1432.	0.7	12
69	Gamma-glutamyl transferase and cardiovascular disease. Annals of Translational Medicine, 2016, 4, 481-481.	0.7	85
70	Mechanical strategies to enhance myocardial salvage during primary percutaneous coronary intervention in patients with STEMI. EuroIntervention, 2016, 12, 319-328.	1.4	17
71	Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention. EuroIntervention, 2016, 11, e1275-e1282.	1.4	0
72	Procedureâ€related bleeding in elective percutaneous coronary interventions. European Journal of Clinical Investigation, 2015, 45, 263-273.	1.7	5

#	Article	IF	Citations
73	Research update for articles published in <scp>EJCI</scp> in 2013. European Journal of Clinical Investigation, 2015, 45, 1005-1016.	1.7	1
74	Improving myocardial injury, infarct size, and myocardial salvage in the era of primary PCI for STEMI. Coronary Artery Disease, 2015, 26, 341-355.	0.3	24
75	Glycosylated hemoglobin at early follow-up and outcome in diabetic patients with ST-segment elevation myocardial infarction. Coronary Artery Disease, 2015, 26, 551-552.	0.3	2
76	Relation of Body Mass Index to Bleeding During Percutaneous Coronary Interventions. American Journal of Cardiology, 2015, 115, 434-440.	0.7	17
77	BMI and coronary heart disease: no difference according to sex. Lancet Diabetes and Endocrinology,the, 2015, 3, 398-400.	5.5	1
78	Minimising bleeding during percutaneous coronary intervention. BMJ, The, 2015, 350, h1395-h1395.	3.0	4
79	Prognostic value of thyroid-stimulating hormone within reference range in patients with coronary artery disease. Metabolism: Clinical and Experimental, 2015, 64, 1308-1315.	1.5	13
80	Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis, 2015, 39, 35-42.	1.0	21
81	Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention. American Heart Journal, 2014, 168, 862-868.e1.	1.2	9
82	Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. Catheterization and Cardiovascular Interventions, 2014, 83, 182-189.	0.7	29
83	Bleeding complications in patients undergoing percutaneous coronary interventions. Coronary Artery Disease, 2014, 25, 247-257.	0.3	19
84	Correlates of poor outcome among patients with bleeding after coronary interventions. Coronary Artery Disease, 2014, 25, 456-462.	0.3	6
85	Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. Cardiovascular Revascularization Medicine, 2014, 15, 131-136.	0.3	14
86	Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease. Clinical Research in Cardiology, 2014, 103, 49-56.	1.5	13
87	Microvascular obstruction in patients with non-ST-elevation myocardial infarction: a contrast-enhanced cardiac magnetic resonance study. International Journal of Cardiovascular Imaging, 2014, 30, 1087-1095.	0.7	17
88	C-reactive protein and prognosis in women and men with coronary artery disease after percutaneous coronary intervention. Cardiovascular Revascularization Medicine, 2013, 14, 264-269.	0.3	10
89	Sex-related effectiveness of bivalirudin versus abciximab and heparin in nonâ€“ST-segment elevation myocardial infarction. American Heart Journal, 2013, 165, 537-543.	1.2	13
90	Bleeding after percutaneous coronary intervention in women and men matched for age, body mass index, and type of antithrombotic therapy. American Heart Journal, 2013, 166, 534-540.	1.2	42

#	Article	IF	Citations
91	Prehospital statin therapy and one-year mortality in patients with stable coronary artery disease undergoing percutaneous coronary intervention. European Journal of Internal Medicine, 2013, 24, 145-150.	1.0	4
92	A gender-specific analysis of association between hyperuricaemia and cardiovascular events in patients with coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 1195-1201.	1.1	34
93	Relation of Fibrinogen Level With Cardiovascular Events in Patients With Coronary Artery Disease. American Journal of Cardiology, 2013, 111, 804-810.	0.7	42
94	Prognostic Value of Access and Nonâ€"Access Sites Bleeding After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 354-361.	1.4	53
95	Prognostic value of uric acid in patients with TypeÂ2 diabetes mellitus and coronary artery disease. Clinical Science, 2013, 124, 259-268.	1.8	19
96	Research update for articles published in <scp>EJCI</scp> in 2011. European Journal of Clinical Investigation, 2013, 43, 1097-1110.	1.7	2
97	Uric acid and prognosis in angiographyâ€proven coronary artery disease. European Journal of Clinical Investigation, 2013, 43, 256-266.	1.7	40
98	Statin pretreatment and presentation patterns in patients with coronary artery disease. Cardiology Journal, 2013, 20, 52-8.	0.5	12
99	Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation, 2012, 125, 1424-1431.	1.6	207
100	Association of coronary atherosclerotic burden with clinical presentation and prognosis in patients with stable and unstable coronary artery disease. Clinical Research in Cardiology, 2012, 101, 1003-1011.	1.5	35
101	Association of uric acid with mortality in patients with stable coronary artery disease. Metabolism: Clinical and Experimental, 2012, 61, 1780-1786.	1.5	55
102	Prognostic Value of Uric Acid in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2012, 109, 1260-1265.	0.7	72
103	ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Cardiology Journal, 2012, 19, 61-69.	0.5	19
104	Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. American Heart Journal, 2011, 161, 68-75.	1.2	90
105	Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes. Clinica Chimica Acta, 2011, 412, 1350-1356.	0.5	16
106	Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina. European Journal of Clinical Investigation, 2011, 41, 1054-1062.	1.7	12
107	High-Sensitivity Troponin T Level and Angiographic Severity of Coronary Artery Disease. American Journal of Cardiology, 2011, 108, 639-643.	0.7	52
108	Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clinical Research in Cardiology, 2011, 100, 327-333.	1.5	16

#	Article	IF	Citations
109	Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clinical Research in Cardiology, 2011, 100, 691-699.	1.5	7
110	Efficacy of reperfusion with primary percutaneous coronary intervention in patients with acute ST segment elevation myocardial infarction. Clinical Research in Cardiology, 2011, 100, 1047-1048.	1.5	1
111	Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction. EuroIntervention, 2011, 7, 128-135.	1.4	8
112	Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention. Heart and Vessels, 2010, 25, 27-34.	0.5	23
113	Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention. Heart and Vessels, 2010, 25, 294-298.	0.5	6
114	Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy. Clinical Research in Cardiology, 2010, 99, 13-19.	1.5	10
115	One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial. Clinical Research in Cardiology, 2010, 99, 795-802.	1.5	22
116	Bleeding After Percutaneous Coronary Intervention With Bivalirudin or Unfractionated Heparin and One-Year Mortality. American Journal of Cardiology, 2010, 105, 163-167.	0.7	25
117	Peak Cardiac Troponin-T Level, Scintigraphic Myocardial Infarct Size and One-Year Prognosis in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. American Journal of Cardiology, 2010, 106, 1212-1217.	0.7	53
118	Predictive Factors and Impact of No Reflow After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2010, 3, 27-33.	1.4	141
119	ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. European Heart Journal, 2010, 31, 2482-2491.	1.0	82
120	5-Year Prognostic Value of No-Reflow Phenomenon After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 2383-2389.	1.2	380
121	Myocardial Perfusion Grade, Myocardial Salvage Indices and Long-Term Mortality in Patients With Acute Myocardial Infarction and Full Restoration of Epicardial Blood Flow After Primary Percutaneous Coronary Intervention. Revista Espanola De Cardiologia (English Ed), 2010, 63, 770-778.	0.4	7
122	Prognostic Value of Kidney Function in Patients With ST-Elevation and Nonâ€“ST-Elevation Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. American Journal of Kidney Diseases, 2009, 54, 830-839.	2.1	25
123	Serum potassium levels on admission and infarct size in patients with acute myocardial infarction. Clinica Chimica Acta, 2009, 409, 46-51.	0.5	8
124	The Only Better Alternative to Rescue Percutaneous Coronary Intervention Is Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2009, 54, 127-129.	1.2	5
125	Patterns of Presentation and Outcomes of Patients with Acute Coronary Syndromes. Cardiology, 2009, 113, 198-206.	0.6	36
126	Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention. Clinical Science, 2009, 116, 651-658.	1.8	22

#	Article	IF	Citations
127	Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. Clinical Research in Cardiology, 2008, 97, 160-168.	1.5	12
128	Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. European Journal of Clinical Investigation, 2008, 38, 90-96.	1.7	86
129	Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. Journal of the American College of Cardiology, 2008, 51, 690-697.	1.2	452
130	Prognostic Significance of Epicardial Blood Flow Before and After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2008, 52, 512-517.	1.2	69
131	Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. American Heart Journal, 2008, 155, 356-360.	1.2	46
132	Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 66-73.	1.1	48
133	Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. European Heart Journal, 2008, 30, 290-296.	1.0	51
134	Accuracy of N-Terminal Probrain Natriuretic Peptide to Predict Mortality or Detect Acute Ischemia in Patients with Coronary Artery Disease. Cardiology, 2008, 109, 249-257.	0.6	6
135	Glycoprotein IIb/IIIa Receptor Inhibition with Abciximab during Percutaneous Coronary Interventions Increases the Risk of Bleeding in Patients with Impaired Renal Function. Cardiology, 2008, 111, 247-253.	0.6	10
136	Evolution of Left Ventricular Ejection Fraction and its Relationship to Infarct Size After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2007, 50, 149-156.	1.2	100
137	Accuracy of N-Terminal Pro-Brain Natriuretic Peptide to Predict Mortality in Various Subsets of Patients With Coronary Artery Disease. American Journal of Cardiology, 2007, 100, 575-578.	0.7	15
138	A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes. Clinical Research in Cardiology, 2007, 96, 30-37.	1.5	14
139	Area under ROC curve, sensitivity, specificity of N-terminal probrain natriuretic peptide in predicting mortality in various subsets of patients with ischemic heart disease. Clinical Research in Cardiology, 2007, 96, 763-765.	1.5	6
140	N-Terminal Probrain Natriuretic Peptide and C-reactive Protein in Stable Coronary Heart Disease. American Journal of Medicine, 2006, 119, 355.e1-355.e8.	0.6	20
141	A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease. Clinica Chimica Acta, 2006, 373, 70-76.	0.5	10
142	N-Terminal Pro-Brain Natriuretic Peptide on Admission in Patients With Acute Myocardial Infarction and Correlation With Scintigraphic Infarct Size, Efficacy of Reperfusion, and Prognosis. American Journal of Cardiology, 2006, 97, 1151-1156.	0.7	29
143	Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. American Journal of Cardiology, 2005, 95, 553-557.	0.7	66
144	Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2005, 293, 2865.	3.8	238

#	Article	IF	Citations
145	Prognostic Value of N-Terminal Proâ€“Brain Natriuretic Peptide in Patients With Chronic Stable Angina. Circulation, 2005, 112, 2102-2107.	1.6	67
146	Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clinica Chimica Acta, 2005, 360, 178-186.	0.5	31
147	Iron status and clinical outcome in patients with coronary artery disease after coronary stenting. Nutrition, Metabolism and Cardiovascular Diseases, 2005, 15, 418-425.	1.1	5
148	Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting. American Heart Journal, 2005, 150, 550-556.	1.2	17
149	Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction. Journal of Nuclear Medicine, 2005, 46, 1782-8.	2.8	22
150	Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. American Journal of Cardiology, 2004, 93, 1201-1206.	0.7	53
151	Myocardial Salvage after Reduced-Dose Thrombolysis Combined with Glycoprotein IIb/IIIa Blockade Versus Thrombolysis Alone in Patients with Acute Myocardial Infarction. Journal of Thrombosis and Thrombolysis, 2004, 17, 191-197.	1.0	3
152	Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus. American Journal of Medicine, 2004, 117, 830-836.	0.6	8
153	Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. Atherosclerosis, 2004, 174, 105-110.	0.4	22
154	Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction. Journal of Nuclear Medicine, 2004, 45, 725-9.	2.8	68
155	Homocysteine Status and Polymorphisms of Methylenetetrahydrofolate Reductase Are Not Associated With Restenosis After Stenting in Coronary Arteries. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 2229-2234.	1.1	23
156	Early Resolution of ST-Segment Elevation Correlates With Myocardial Salvage Assessed by Tc-99m Sestamibi Scintigraphy in Patients With Acute Myocardial Infarction After Mechanical or Thrombolytic Reperfusion Therapy. Circulation, 2002, 105, 2946-2949.	1.6	86
157	Mapping studies in atrial fibrillation. Herzschrittmachertherapie Und Elektrophysiologie, 2002, 13, 186-194.	0.3	0
158	Alkaline phosphatase and cardiovascular disease. Journal of Laboratory and Precision Medicine, 0, 2, 83-83.	1.1	7
159	Alanine aminotransferaseâ€”a marker of cardiovascular risk at high and low activity levels. Journal of Laboratory and Precision Medicine, 0, 4, 29-29.	1.1	18